Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B
- PMID: 26823276
- DOI: 10.1111/hae.12878
Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B
Abstract
Introduction: Limited data are available on optimal prophylaxis regimens of factor IX (FIX) replacements for patients with haemophilia B.
Aim: This multicentre, open-label study evaluated the efficacy and safety of once-weekly prophylaxis with nonacog alfa compared with on-demand treatment in adolescent and adult patients.
Methods: Males aged 12-65 years with moderately severe to severe haemophilia B (FIX:C ≤ 2%) were eligible for enrolment. Patients received on-demand treatment for 26 weeks, followed by once-weekly prophylaxis of 100 IU kg(-1) for 52 weeks. The primary efficacy end point was the annualized bleeding rate (ABR). Secondary end points included response to on-demand treatment, the number of infusions used to treat bleeding events, and the incidence of less-than-expected therapeutic effect (LETE). FIX:C was measured on day 1 and at weeks 26 and 78.
Results: Mean (±SD) ABR was lower during prophylaxis vs. on-demand treatment [3.6 (±4.6) vs. 32.9 (±17.4) events, respectively; P < 0.0001]. The majority (88.4%) of bleeding events had excellent or good responses upon the first infusion; 82.1% of events responded to the first infusion. No incident of LETE occurred. No thrombotic events or FIX inhibitors were reported. Eight of 17 FIX:C approximately 1 week after dosing were >2 IU dL(-1) (min-max of 2.13-10.39 IU dL(-1) ).
Conclusions: Once-weekly prophylaxis of 100 IU kg(-1) was associated with lower ABR compared with on-demand treatment in adolescents and adults with moderately severe to severe haemophilia B. Once-weekly prophylaxis was well tolerated, with a similar safety profile as that reported during the on-demand treatment period. Residual FIX:C may be supportive of effectiveness.
Keywords: BeneFIX; factor IX; haemophilia B; pharmacokinetics; prevention; safety.
© 2016 The Authors. Haemophilia Published by John Wiley & Sons Ltd.
Similar articles
-
Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects.Haemophilia. 2014 May;20(3):398-406. doi: 10.1111/hae.12344. Epub 2014 Jan 13. Haemophilia. 2014. PMID: 24418368 Clinical Trial.
-
Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.Haemophilia. 2016 Jul;22(4):507-13. doi: 10.1111/hae.12902. Epub 2016 Mar 3. Haemophilia. 2016. PMID: 26936227 Clinical Trial.
-
Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.Haemophilia. 2016 Jul;22(4):e267-74. doi: 10.1111/hae.12995. Epub 2016 Jun 28. Haemophilia. 2016. PMID: 27352908 Clinical Trial.
-
Nonacog Beta Pegol: A Review in Haemophilia B.Drugs. 2017 Dec;77(18):2003-2012. doi: 10.1007/s40265-017-0836-8. Drugs. 2017. PMID: 29124682 Free PMC article. Review.
-
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B.J Blood Med. 2016 Nov 30;7:275-282. doi: 10.2147/JBM.S84597. eCollection 2016. J Blood Med. 2016. PMID: 27942241 Free PMC article. Review.
Cited by
-
Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.Adv Ther. 2024 Jun;41(6):2307-2323. doi: 10.1007/s12325-024-02841-w. Epub 2024 Apr 23. Adv Ther. 2024. PMID: 38652439 Free PMC article.
-
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany.Pharmacoecon Open. 2024 May;8(3):373-387. doi: 10.1007/s41669-024-00480-z. Epub 2024 Mar 23. Pharmacoecon Open. 2024. PMID: 38520664 Free PMC article. Review.
-
A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B.J Blood Med. 2024 Mar 5;15:113-122. doi: 10.2147/JBM.S425617. eCollection 2024. J Blood Med. 2024. PMID: 38481741 Free PMC article.
-
Expanding Pharmacy Services to the Hemophilia Treatment Center.Hosp Pharm. 2023 Oct;58(5):415-419. doi: 10.1177/00185787231163262. Epub 2023 Apr 13. Hosp Pharm. 2023. PMID: 37711404
-
Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B.Glob Reg Health Technol Assess. 2020 Jul 14;7:40-49. doi: 10.33393/grhta.2020.2113. eCollection 2020 Jan-Dec. Glob Reg Health Technol Assess. 2020. PMID: 36627960 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources